ijms-logo

Journal Browser

Journal Browser

Special Issue "Interleukins in Allergic and Immune-Mediated Diseases: A Cascade of Multiple Shadows"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 30 November 2021.

Special Issue Editors

Prof. Dr. Giuseppe Murdaca
E-Mail Website
Guest Editor
Department of Internal Medicine, Clinical Immunology Unit, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy
Interests: immunodeficiency; autoimmunity; neuro-endocrino-immunology; pharmacogenomics
Special Issues and Collections in MDPI journals
Dr. Sebastiano Gangemi
E-Mail Website
Guest Editor
School and Division of Allergy and Clinical Immunology, Department of Experimental Medicine, University of Messina, Messina, Italy
Interests: inflammatory mediators; the citokine network (interleukins, chemokines, adhesion molecules, lipoxines); the oxidative stress in various areas of clinical immunology; allergy; oncology
Special Issues and Collections in MDPI journals
Dr. Monica Greco
E-Mail
Guest Editor
Clinical Immunology Unit, Department of Internal Medicine, University of Genova and, Ospedale Policlinico San Martino, Genova, Italy
Interests: immune system; autoimmune diseases
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Several allergic and immunologic diseases, including asthma, food allergy (FA), chronic spontaneous urticaria (CSU), atopic dermatitis (AD), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), multiple sclerosis (MS), and inflammatory bowel diseases (IBDs), are characterized by the involvement of Th2 immunity. Several mediators lead to IgEs production, thus including key cytokines like IL-4, IL-5, IL-13. Other molecules, such as IL-6, IL-21, and IL-23, are involved in Th-17 pathway, thus leading to IL-17 production which mediates tissue inflammation and autoimmunity. On the other hand, IL-2 is involved in T regular (T reg) cell activation with consequent production of IL-10, which seems to regulate tolerance and immune suppression. Moving through this complex scenario, some of these molecules, such as IL-5, have already been studied as novel biomarkers for specific targeted therapies. Indeed, inhibition or stimulation in case of protective function of these molecules could represent a promising option for future therapies. In the near future, new studies investigating the role of these molecules as part of a complex and wide biological net are needed in order to understand the role of these molecules on biological systems.

Prof. Dr. Giuseppe Murdaca
Assoc. Pro Sebastiano Gangemi
Dr. Monica Greco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma
Int. J. Mol. Sci. 2021, 22(16), 9039; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22169039 - 21 Aug 2021
Viewed by 517
Abstract
Objective: Multiple Myeloma (MM) is a haematological disease resulting from the neoplastic transformation of plasma cells. The uncontrolled growth of plasma cells in the bone marrow and the delivery of several cytokines causes bone erosion that often does not regress, even in the [...] Read more.
Objective: Multiple Myeloma (MM) is a haematological disease resulting from the neoplastic transformation of plasma cells. The uncontrolled growth of plasma cells in the bone marrow and the delivery of several cytokines causes bone erosion that often does not regress, even in the event of disease remission. MM is characterised by a multi-step evolutionary path, which starts with an early asymptomatic stage defined as monoclonal gammopathy of undetermined significance (MGUS) evolving to overt disease. Data Sources and Study Selection: We have selected scientific publications on the specific topics “alarmis, MGUS, and MM”, drawing from PubMed. The keywords we used were alarmines, MGUS, MM, and immune system. Results: The analysis confirms the pivotal role of molecules such as high-mobility group box-1, heat shock proteins, and S100 proteins in the induction of neoangiogenesis, which represents a milestone in the negative evolution of MM as well as other haematological and non-haematological tumours. Conclusions: Modulation of the host immune system and the inhibition of neoangiogenesis may represent the therapeutic target for the treatment of MM that is capable of promoting better survival and reducing the risk of RRMM. Full article
Show Figures

Figure 1

Back to TopTop